5 More Possible Partners For MannKind's Afrezza, Each With A Strong Diabetes Care Franchise
However, in all but one case, Afrezza may compete with their strongest and most profitable existing drug or with new drugs in their pipelines.
Trending on the Topix Network
Sat Jul 19, 2014
Recent Tsunami of Insider Shares Purchased: A Prelude To Mannkind Partnership or Acquisition
The prior day's massive insider shares purchased lend support to investor's sentiment that Mannkind would finalize potential buyout or partnership negotiation soon, and this would unlock significant value for shareholders.
Thu Jul 17, 2014
Insider Selling: Diane Palumbo Unloads 17,901 Shares of MannKind Stock
MannKind VP Diane Palumbo unloaded 17,901 shares of the stock in a transaction that occurred on Tuesday, July 15th.
MannKind Trading Down 3.4% After Insider Selling
MannKind fell 3.4% on Thursday after an insider sold shares in the company, Analyst Ratings Net reports.
Most Active Options Update: Micron Technology, Inc.
The 20 stocks listed in the table below have attracted the highest total options volume during the past 10 trading days.
Wed Jul 16, 2014
Mannkind Corporation: Why Afrezza Would Completely Dominate The Insulin Market
Mannkind Corporation is a small company based in Valencia, California, focusing on the development and commercialization of medicine to treat diabetes.
AntriaBio Presents Vast Upside With Disruptive Once-Weekly Insulin
AntriaBio's once-weekly insulin injection is in early-stage development, but as the examples used have shown, potentially disruptive drugs candidates have warranted rich valuations even at early stages.
Mon Jul 14, 2014
MannKind: Are These Top Big Pharma Companies Potential Partners?
The ideal partner would be a large, global company with a strong presence in the diabetes care niche but with no product whose sales would be threatened by a successful Afrezza.
Fri Jul 11, 2014
The Motley Fool
Is This MannKind's Greatest Risk?
Instead, those predictions swung and missed. The U.S. Food and Drug Administration recently approved the inhaled insulin.
Fri Jul 04, 2014
The Motley Fool
3 Things to Look for in MannKind's Partnership
What's taking so long? I jest. But I'm allowed to. MannKind has been talking about a partnership since before the FDA first rejected the drug f Without a doubt, a partnership is the next big catalyst for the stock now that Afrezza is approved.
Diabetes Self Management
FDA Approves Inhalable Insulin
On June 27, the US Food and Drug Administration approved Afrezza, a first-in-class inhalable insulin/inhaler combination, for adults with diabetes.
Thu Jul 03, 2014
MannKind CFO Matthew J. Pfeffer Sells 20,000 Shares
MannKind CFO Matthew J. Pfeffer sold 20,000 shares of the company's stock in a transaction dated Tuesday, July 1st.
MannKind Corp Analyst Report; Afrezza is Approved and Future...
MannKind Corporation is a biopharmaceutical company focused on the discovery and development of therapeutic products for diseases such as diabetes.
The Zacks Analyst Blog Highlights: Vertex Pharmaceuticals, MannKind,...
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets.
Wed Jul 02, 2014
Insider Buying: Hakan Edstrom Buys 1,692 Shares of MannKind Stock
MannKind COO Hakan Edstrom purchased 1,692 shares of MannKind stock in a transaction dated Monday, June 30th.
Tue Jul 01, 2014
Inhaled Insulin Afrezza: FAQ
June 30, 2014 -- Millions of people with type 1 or type 2 diabetes will have another treatment option now that the FDA has approved an inhaled insulin .
Why MannKind Corporation (MNKD) Bears Aren't Panicking
Despite the FDA-inspired boost, though, MNKD bears don't seem to be panicking just yet.
MLV & Co. Downgrades MannKind On Fair Valuation
In a report published Tuesday, MLV & Co analyst Graig C. Suvannavejh downgraded the rating on MannKind Corporation from Buy to Hold, but raised the price target from $10.00 to $11.00.
Mon Jun 30, 2014
Week Ahead Market Report: June 30, 2014
The US markets are mixed this afternoon, with the Dow down 0.02%, the S&P up 0.12% and the Nasdaq higher by 0.43%.
FDA Approves MannKind's Afrezza; Synageva BioPharma Reports Phase 3...
Afrezza, a fast-acting form of insulin, for adults with the most common form of diabetes, which affects more than 25 million Americans.